Venlafaxine ER
Phase 3Small molecule
PfizerVenlafaxine ER is one of 126 small molecule programs targeting Panic Disorder. It is currently in Phase 3.
4
Indications
10
Total Trials
0
Active Trials
125
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
SAGE-217
BiogenPhase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Brenipatide
Eli LillyPhase 3
Seltorexant
Johnson & JohnsonPhase 3
Venlafaxine ER
PfizerPhase 3
Seroquel IR
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Disorder2 trials
Panic Disorder2 trials
Randomized1 trial
3 more indications
Tics1 trial
Generalized Anxiety Disorder1 trial
Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)
Terminated·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00083980·16 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Venlafaxine ER. EMBL-EBI & Wellcome Sanger Institute.
- [4]